Spots Global Cancer Trial Database for Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer
Official Title: A Phase 1 Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL999 Administered Intravenously to Subjects With Non-Small-Cell Lung Cancer (NSCLC)
Study ID: NCT00491699
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the safest dose of XL999 and how well subjects with Non-Small-Cell Lung Cancer tolerate XL999. XL999 is a small molecule inhibitor of multiple kinases including VEGFR, PDGFR, FGFR, FLT-3, and Src, which are involved in tumor cell growth, formation of new blood vessels (angiogenesis), and metastasis.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Medical Center, Los Angeles, California, United States
Peachtree Hematology Oncology Consultants, Atlanta, Georgia, United States
Wayne State University, Karmanos Cancer Institute, Detroit, Michigan, United States
Hematology-Oncology Associates of Rockland, Nyack, New York, United States
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States
Contact Details
Name: Lynne A. Bui, MD
Affiliation: Exelixis
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
